Short Interest in Audentes Therapeutics Inc (BOLD) Rises By 71.6%

Audentes Therapeutics Inc (NASDAQ:BOLD) saw a significant growth in short interest during the month of January. As of January 31st, there was short interest totalling 1,655,460 shares, a growth of 71.6% from the January 12th total of 964,664 shares. Approximately 6.9% of the shares of the company are sold short. Based on an average daily volume of 633,577 shares, the days-to-cover ratio is currently 2.6 days.

In related news, Director Louis G. Lange sold 18,000 shares of the stock in a transaction that occurred on Friday, December 22nd. The stock was sold at an average price of $30.88, for a total transaction of $555,840.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, SVP Mary Newman sold 10,000 shares of the stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $26.84, for a total value of $268,400.00. The disclosure for this sale can be found here. Insiders sold 36,000 shares of company stock worth $1,052,480 in the last ninety days. 47.30% of the stock is owned by company insiders.

Hedge funds have recently modified their holdings of the business. SG Americas Securities LLC acquired a new stake in shares of Audentes Therapeutics in the 3rd quarter valued at $143,000. Teacher Retirement System of Texas acquired a new stake in shares of Audentes Therapeutics in the 4th quarter valued at $208,000. Nationwide Fund Advisors boosted its holdings in shares of Audentes Therapeutics by 288.9% in the 2nd quarter. Nationwide Fund Advisors now owns 8,594 shares of the biotechnology company’s stock valued at $164,000 after purchasing an additional 6,384 shares in the last quarter. Trexquant Investment LP acquired a new stake in shares of Audentes Therapeutics in the 3rd quarter valued at $295,000. Finally, Virtus Fund Advisers LLC acquired a new stake in shares of Audentes Therapeutics in the 4th quarter valued at $372,000. 64.76% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities research analysts recently issued reports on BOLD shares. William Blair started coverage on Audentes Therapeutics in a research report on Tuesday, October 17th. They set an “outperform” rating and a $35.00 price target on the stock. Zacks Investment Research raised Audentes Therapeutics from a “sell” rating to a “hold” rating in a research report on Monday, October 23rd. Leerink Swann reissued an “outperform” rating and set a $29.00 price target (up previously from $22.00) on shares of Audentes Therapeutics in a research report on Wednesday, November 15th. ValuEngine downgraded Audentes Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Finally, BMO Capital Markets started coverage on Audentes Therapeutics in a research report on Tuesday, December 5th. They set an “outperform” rating and a $35.00 price target on the stock. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $35.00.

Shares of Audentes Therapeutics (BOLD) opened at $31.33 on Friday. The firm has a market capitalization of $933.88 and a price-to-earnings ratio of -9.00. Audentes Therapeutics has a twelve month low of $13.90 and a twelve month high of $41.80.

Audentes Therapeutics (NASDAQ:BOLD) last issued its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.88) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.88). equities research analysts predict that Audentes Therapeutics will post -3.5 earnings per share for the current year.

WARNING: “Short Interest in Audentes Therapeutics Inc (BOLD) Rises By 71.6%” was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece on another site, it was stolen and republished in violation of United States and international copyright law. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2018/02/11/short-interest-in-audentes-therapeutics-inc-bold-rises-by-71-6.html.

About Audentes Therapeutics

Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).

Receive News & Ratings for Audentes Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Audentes Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply